Eiger Biopharmaceuticals Inc (EIGR) Receives $34.50 Average Target Price from Analysts

Shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) have earned a consensus rating of “Buy” from the nine research firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $34.50.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. ValuEngine downgraded Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 18th. Finally, Wedbush set a $43.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, April 12th.

In related news, Director Thomas John Dietz acquired 5,000 shares of the stock in a transaction dated Monday, April 22nd. The shares were acquired at an average price of $11.05 per share, with a total value of $55,250.00. Following the acquisition, the director now owns 15,000 shares in the company, valued at approximately $165,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have bought 7,250 shares of company stock worth $80,130. 5.80% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlueCrest Capital Management Ltd raised its position in Eiger Biopharmaceuticals by 34.9% in the 1st quarter. BlueCrest Capital Management Ltd now owns 21,250 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 5,496 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Eiger Biopharmaceuticals by 17.3% in the 1st quarter. Morgan Stanley now owns 62,026 shares of the biotechnology company’s stock valued at $867,000 after purchasing an additional 9,146 shares in the last quarter. Jefferies Group LLC bought a new position in shares of Eiger Biopharmaceuticals in the 1st quarter valued at $164,000. ExodusPoint Capital Management LP lifted its stake in shares of Eiger Biopharmaceuticals by 169.6% in the 1st quarter. ExodusPoint Capital Management LP now owns 38,826 shares of the biotechnology company’s stock valued at $543,000 after acquiring an additional 24,426 shares during the last quarter. Finally, Broadfin Capital LLC lifted its stake in shares of Eiger Biopharmaceuticals by 34.9% in the 1st quarter. Broadfin Capital LLC now owns 193,300 shares of the biotechnology company’s stock valued at $2,702,000 after acquiring an additional 50,000 shares during the last quarter. 79.67% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ EIGR opened at $11.51 on Monday. Eiger Biopharmaceuticals has a 1-year low of $8.40 and a 1-year high of $15.33. The company has a current ratio of 8.16, a quick ratio of 8.16 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $220.15 million, a price-to-earnings ratio of -3.01 and a beta of 1.35.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.90) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $0.05. Sell-side analysts anticipate that Eiger Biopharmaceuticals will post -2.75 EPS for the current fiscal year.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: What is the Consumer Price Index (CPI)?

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply